New drug cocktail targets Hard-to-Treat cancers

NCT ID NCT05396833

Ongoing Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body processes the drugs. About 120 participants will take part across several groups, each focusing on different cancer types or drug combinations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tuvusertib (M1774) combined with lartesertib or avelumab

What this could lead to

If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.

What could go wrong

This is a very early (Phase 1) trial focused on safety and dosing, not on proving the drugs work. Many drug combinations fail at this stage, and side effects may be significant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma colorectal cancer endometrial cancer metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis ovarian carcinoma prostate cancer triple-negative breast carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC OR LOCALLY ADVANCED UNRESECTABLE SOLID TUMORS

Contacts and locations

Show contact details

Locations

Asan Medical Center

Seoul, 05505, South Korea
Augusta University - formerly Georgia Regents University

Augusta, Georgia, 30912, United States
Calvary Mater Newcastle - PARENT

Waratah, Australia
Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica

Madrid, 28050, Spain
Hospital Clinic de Barcelona - Servicio de Oncologia

Barcelona, Spain
Hospital QuironSalud Barcelona - Next Oncology

Barcelona, 08023, Spain
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I

Madrid, Spain
Hospital Universitario Quironsalud Madrid - NEXT Oncology

Madrid, 28223, Spain
Korea University Guro Hospital

Seoul, 08308, South Korea
Mary Crowley Cancer Research Centers

Dallas, Texas, 75230, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
Princess Margaret Cancer Centre

Toronto, M5G 2C1, Canada
Providence Medical Foundation

Santa Rosa, California, 95403, United States
Royal North Shore Hospital

St Leonards, Australia
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Bundang Hospital

Seongnam-si, 13620, South Korea
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases

Seoul, 03722, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, 06591, South Korea
The University of Kansas Medical Center Research Institute, Inc.

Kansas City, Kansas, 66205, United States
University of Miami School of Medicine

Miami, Florida, 33136, United States
University of Texas M. D. Anderson Cancer Center - Partner

Houston, Texas, 77030, United States